BriaCell Therapeutics Corp. (BCTX) Form 10-K — Oct 28, 2026
BriaCell filed its FY2026 10-K with explicit going-concern language: net losses widened to $34.9M from $26.3M the prior year and the accumulated deficit reached $146.7M, with management stating current cash will not fund anticipated operations without additional financing. On the pipeline side, Bria-IMT plus a checkpoint inhibitor is in a pivotal Phase 3 study (NCT06072612) with FDA Fast Track designation, and reported Phase 2 median overall survival of 13.3 months (16.6 months for patients treated since 2022) versus 5.9-9.8 months for similar patients in the literature.
Key figures
- Total Debt
- 0
- Shares Outstanding
- 8732381
- Prior year net loss
- 26311867
- Bria pro ownership pct
- 71.13%
- Bria ims median os months
- 13.3
- Accumulated deficit fy2025
- 111755564
- Accumulated deficit fy2026
- 146659826
- Non affiliate market value
- 37400450
- Median os since 2022 months
- 16.6
- Philadelphia monthly lease usd
- 43500
- Literature comparator os months
- 5.9-9.8
- Options warrants rsu shares outstanding
- 8462889
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.